FindTrial
Sign In

The influence of ultrasound sclerotherapy in patient with hydrosalpinx undergoing IVF-ET treatment

The influence of ultrasound sclerotherapy in patient with hydrosalpinx undergoing IVF-ET treatment

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOC-17013968
Enrollment
Unknown
Registered
2017-12-15
Start date
2018-01-01
Completion date
Unknown
Last updated
2017-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hydrosalpinx

Interventions

Surgery group:Surgery
centesis:Ultrasound-guided sclerotherapy

Sponsors

Reproductive Medicine Center, The 105th Hospital of PLA
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 37 Years

Inclusion criteria

Inclusion criteria: 1. Patients with unilateral or bilateral hydrosalpinges visible by ultrasound; 2. Aged between 20 - 37 years; 3. Period of infertility > 1 year; 4. Body mass index between 19-29; 5. Normal basal luteinizing hormone (LH), follicle stimulating hormone (FSH) and prolactin concentrations; 6. AFC=7; 7. AMH level 0.24-11.78ng/ml; 8. midluteal phase gonadotropin-releasing hormone agonist (GnRH-a) long down-regulation protocol.

Exclusion criteria

Exclusion criteria: 1. Allergy to alcohol; 2. Uterine fibroid requiring surgical removal; 3. Chocolate cyst or adenomyosis; 4. Pelvic tuberculosis; 5. Endocrinologic disorders; 6. Presence of systemic disease contraindicating pregnancy.

Design outcomes

Primary

MeasureTime frame
clinical pregnancy rate;—

Secondary

MeasureTime frame
recurrent rate;Pregnancy Loss rate;live birth rate;—

Countries

China

Contacts

Public ContactWei He

The First Hospital Affiliated to Army Medical University (Southwest Hospital)

anyhewei@163.com+86 13608356955

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026